ROS1 and non-small cell lung carcinoma: The multi-target TKIs entrectinib and crizotinib are current first-line standard-of-care treatments for advanced ROS1 fusion-positive NSCLC.191 Following impressive results in the registrational phase 1-2 trial TRIDENT-1, in November 2023, the US FDA approved repotrectinib for treatment with locally advanced/metastatic ROS-1-positive NSCLC.192,193